Oncology Links From Across the Web for Bone Mets

Damian Dupuy, MD

//Award Winners

Radiofrequency Pioneer Heralded

A Rhode Island physician and researcher credited with expanding the use of radiofrequency ablation (RFA) to alleviate metastatic bone pain in cancer patients has been honored by the American College of Radiology Imaging Network (ACRIN).

Damian Dupuy, MD, is the director of Ultrasound in the Department of Diagnostic Imaging at Rhode Island Hospital, as well as a professor of Diagnostic Imaging at Brown Medical School. He is recognized as a pioneer in the field of RFA.

Originally developed and approved for ablation in liver tumors, RFA is image-guided technology that uses heat to kill tumor cells. After the FDA approved the technology in 1997, Dupuy explored ways to use the minimally invasive option to treat breast, kidney, lung, adrenal, and bone cancers.

He recently led a multicenter study focusing on the safety and efficacy of RFA in reducing bone pain in patients with bone metastases. As a result, ACRIN honored Dupuy with its Publications Merit Award.

Press Release

//Clinical Trials

F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases

STUDY TYPE: Observational

AGE/SEX REQUIREMENT: >18 years (none)

SPONSOR: Seattle Nuclear Medicine

CLINICALTRIALS.GOV IDENTIFIER: NCT01254929

PURPOSE:The study will compare 18F-fluoride positron emission tomography (PET) bone scans with traditional 99mTc-methylene diphosphonate (MDP) bone scans. Objectives include determining any significant differences between the 2 tests, and then establishing whether there is a significant change in the clinical management of the bone metastases. The study also will measure and compare any uncertain findings that may have led to additional testing, quantify any adverse effects from either scan, and perform subgroup analyses based on the cancer cell type. Clinical Trials